- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.BioSpace · 2d ago↗ source
- MDCG: Only manufacturers should assign UDI-DIs<p>The European Commission's Medical Device Coordination Group (MDCG) says unique device identifiers and device identifiers (UDI-DI) codes used between manufacturers and distributors need to be bet…raps · 2d ago↗ source
- FDA issues untitled letters to Sanofi and Viatris for false advertising<p>The FDA’s Office of Prescription Drug Promotion recently reprimanded Sanofi and Viatris for making misleading claims about their products in emails and a television advertisement.</p>